Abstract
Biochemical assays and single case reports show partial recovery of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function in the class II mutation N1303K (p.Asn1303Lys, c.3909C >G) under triple combination with elexacaftor/tezacaftor/ivacaftor (ETI). However this therapy is not approved for patients carrying the mutation outside of heterozygosity with F508del.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
